GGrantIndex
← Search

Synthetic Applications of Formal [3+3] Cycloadditions

$328,675R01FY2004NSNIH

University Of Minnesota Twin Cities, Minneapolis MN

Investigators

Linked publications & trials

Abstract

[unreadable] DESCRIPTION (provided by applicant): In the previous proposal, we identified the formal [3 + 3] cycloaddition as a viable approach to arisugacin A, a potent inhibitor of acetylcholinesterase [AChE]. We also recognized the potential of the [3 + 3] reaction as a general methodology for constructing heterocycles including nitrogen heterocycles. We have accomplished those goals. [unreadable] [unreadable] To demonstrate the usefulness of this formal cycloaddition methodology, pursuing its applications in natural product syntheses has become an important focus. Thus, in this competitive renewal, in addition to furthering the medicinal knowledge of arisugacin A for dementias as originally proposed, we intend to pursue syntheses of natural products containing oxygen heterocycles, and to develop a visible program around alkaloid synthesis particularly using the formal aza-[3 + 3] cycloaddition. While we are pursuing several different endeavors, this renewal focuses on selected topics to best illustrate these efforts, and is organized in the following four aims. [unreadable] [unreadable] Specific Aim 1 [Aim 3 in the previous proposal] focuses on synthesis of analogs of arisugacin A using the formal oxa-[3 + 3] cycloaddition and in vitro assay of the analogs to explore binding of arisugacin A to AChE. [unreadable] [unreadable] Specific Aim 2 focuses on applications of formal oxa-[3 + 3] cycloadditions in total syntheses of the natural products hongoquercin A and phomactin A. [unreadable] [unreadable] Specific Aim 3 focuses on employing the oxa-[3 + 3] along with the carbo-[3 + 3] formal cycloaddition toward the synthesis of the hyperforin family of natural products. [unreadable] [unreadable] Specific Aim 4 focuses on applications of formal aza-[3 + 3] cycloadditions toward total syntheses of lepadins and cylindricines, and further development of the intramolecular formal aza-[3 + 3] cycloaddition including its asymmetric variants using chiral Lewis acids and amine salts. [unreadable] [unreadable]

View original record on NIH RePORTER →